JO
SGMT icon

John Overdeck’s Sagimet Biosciences SGMT Stock Holding History

John Overdeck’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$633K Buy
81,902
+41,770
+104% +$284K ﹤0.01% 3984
2026
Q1 		$210K Sell
40,132
-2,400
-6% -$13.4K ﹤0.01% 4263
2025
Q4 		$252K Sell
42,532
-8,659
-17% -$62.2K ﹤0.01% 3669
2025
Q3 		$351K Buy
51,191
+38,146
+292% +$309K ﹤0.01% 3147
2025
Q2 		$99.4K Sell
13,045
-36,804
-74% -$155K ﹤0.01% 3000
2025
Q1 		$163K Sell
49,849
-584
-1% -$2.45K ﹤0.01% 2895
2024
Q4 		$227K Sell
50,433
-133,205
-73% -$675K ﹤0.01% 2835
2024
Q3 		$509K Buy
183,638
+109,654
+148% +$338K ﹤0.01% 2467
2024
Q2 		$253K Sell
73,984
-1,237
-2% -$5.67K ﹤0.01% 2655
2024
Q1 		$408K Buy
75,221
+31,321
+71% +$225K ﹤0.01% 2425
2023
Q4 		$238K Buy
+43,900
New +$207K ﹤0.01% 2770

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

John Overdeck's SGMT Position: Q2 2026 in Review

John Overdeck increased its Sagimet Biosciences (SGMT) stake by 104% in Q2 2026, buying an estimated $284K and bringing the position to 81,902 shares worth $633K. The position accounts for ﹤0.01% of the portfolio, ranked #3984.

John Overdeck first reported a position in SGMT in Q4 2023 and has held it in 11 quarters since. 121 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • John Overdeck held 81,902 shares of Sagimet Biosciences worth $633K as of Q2 2026.
  • John Overdeck bought 41,770 Sagimet Biosciences shares in Q2 2026, an estimated $284K.
  • Sagimet Biosciences made up ﹤0.01% of John Overdeck's portfolio in Q2 2026, its #3984 holding.
  • John Overdeck first reported a position in Sagimet Biosciences in Q4 2023 and has held it in 11 quarters since.
  • 121 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.